High avidity cytotoxic t lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Brentville, Victoria A ^a   Metheringham, Rachael L ^a   Gunn, Barbara ^a   Durrant, Lindy G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPITOPE; PEPTIDE VACCINE; PROGRAMMED DEATH 1 RECEPTOR; SERYLVALYLTYROSYLASPARTYLPHENYLALANYLPHENYLALANYLVALYLTRYPTOPHYLLEUCINE VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL LOSS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DOSE RESPONSE; EX VIVO STUDY; FEMALE; GENE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LAG 3 GENE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION GENE 3; LYMPHOCYTE PROLIFERATION; MEMORY; MOUSE; NEUROPHYSIOLOGICAL RECRUITMENT; NONHUMAN; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION; VIRAL CLEARANCE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

MUS;

EID: 84864058737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041112     Document Type: Article

References (42)

1. Alexander-Miller MA, Leggatt GR, Berzofsky JA, (1996) Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 93: 4102-4107.
2. Dutoit V, Rubio-Godoy V, Dietrich P, Quiqueres A, Schnuriger V, et al. (2001) Heterogeneous T-cell response to MAG-A10254-262: High avidity-specific cytolytic T lymphocytes show superior antitumour activity. Cancer Res 61: 5850-5853.
3. Zeh HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC, (1999) High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immuno 162: 989-994.
4. Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, et al. (2003) Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res 63: 5601-5606.
5. Durrant LG, Pudney V, Spendlove I, Metheringham RL, (2010) Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses. Expert Opin Biol Ther 10: 735-748.
6. Sandberg JK, Franksson L, Sundback J, Michaelsson J, Petersson M, et al. (2000) T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol 165: 25-33.
7. Gallimore A, Glitheo A, Godkin A, Tissot AC, Pluckthun A, et al. (1998) Induction and Exhaustion of Lymphocytic Choriomeningitis Virus-specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric \Major Histocompatibility Complex Class I-Peptide Complexes. J Exp Med 187: 1383-1393.
8. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD, (1999) Isolation of high avidity melanoma-reactive CTL from heterogenous populations using peptide-MHC tetramers. J Immunol 162: 2227-2234.
9. Sedlik C, Dadaglio G, Saron MF, Deriaud E, Rojas M, et al. (2000) In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 74: 5769-5775.
10. Terheyden P, Schrama D, Pedersen LO, Andersen MH, Kampgen E, et al. (2003) Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression. Scand J Immunol 58: 566-571.
11. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, et al. (2007) Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27: 670-684.
12. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R, (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 4911-4927.
13. Derby MA, Snyder JT, Tse R, Alexander-Miller MA, Berzofsky JA, (2001) An abrupt and concordant initiation of apoptosis: antigen-dependent death of CD8+ CTL. Eur J Immunol 31: 2951-2959.
14. Pudney VA, Metheringham RL, Gunn B, Spendlove I, Ramage JM, et al. (2010) DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells. Eur J Immunol 40: 899-910.
15. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, et al. (2009) Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 182: 6659-6669.
16. Slifka MK, Whitton JL, (2001) Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol 2: 711-717.
17. Rocha B, Tanchot C, (2006) The Tower of Babel of CD8+ T-cell memory: known facts, deserted roads, muddy waters, and possible dead ends. Immunol Rev 211: 182-196.
18. Stoklasek TA, Colpitts SL, Smilowitz HM, Lefrancois L, (2010) MHC class I and TCR avidity control the CD8 T cell response to IL-15/IL-15Ralpha complex. J Immunol 185: 6857-6865.
19. Hill AB, Blanden RV, Parrish CR, Mullbacher A, (1992) Restimulated memory Tc cells have a higher apparent avidity of interaction with targets than primary virus-immune Tc cells as indicated by anti-CD8 blocking. Immunol Cell Biol 70 (Pt 4): 259-265.
20. Turner MJ, Jellison ER, Lingenheld EG, Puddington L, Lefrancois L, (2008) Avidity maturation of memory CD8 T cells is limited by self-antigen expression. J Exp Med 205: 1859-1868.
21. Aichele P, Brduscha-Riem K, Oehen S, Odermatt B, Zinkernagel RM, et al. (1997) Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6: 519-529.
22. Aichele P, Brduscha-Riem K, Zinkernagel RM, Hengartner H, Pircher H, (1995) T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 182: 261-266.
23. Toes REM, Offringa R, Blom RJJ, Melief CJM, Kast WM, (1996) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proceedings of the National Academy of Science in the USA 93: 7855-7860.
24. Muraoka D, Kato T, Wang L, Maeda Y, Noguchi T, et al. (2010) Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J Immunol 185: 3768-3776.
25. den Boer AT, Diehl L, van Mierlo GJ, van der Voort EI, Fransen MF, et al. (2001) Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol 167: 2522-2528.
26. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, et al. (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111: 236-242.
27. Xavier R, Brennan T, Li Q, McCormack C, Seed B, (1998) Membrane compartmentation is required for efficient T cell activation. Immunity 8: 723-732.
28. Cawthon AG, Alexander-Miller MA, (2002) Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J Immunol 169: 3492-3498.
29. Cawthon AG, Lu H, Alexander-Miller MA, (2001) Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8αβ versus CD8αα expression. J Immunol 167: 2577-2584.
30. Kroger CJ, Alexander-Miller MA, (2007) Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter. Immunology 122: 167-178.
31. Alexander-Miller MA, Derby MA, Sarin A, Henkart PA, Berzofsky JA, (1998) Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J Exp Med 188: 1391-1399.
32. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA, (1996) Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 184: 485-492.
33. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, et al. (2001) B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 193: 839-846.
34. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034.
35. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, et al. (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169: 5538-5545.
36. Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, et al. (2007) Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 110: 186-192.
37. Liu Y, Xu L, Jiang Y, Sun J, He X, (2007) Phenotypic and functional analysis of LCMV gp33-41-specific CD8 T cells elicited by multiple peptide immunization in mice revealed the up-regulation of PD-1 expression on antigen-specific CD8 T cells. Cell Mol Immunol 4: 431-437.
38. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
39. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544.
40. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, et al. (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182: 5240-5249.
41. Chapon M, Randriamampita C, Maubec E, Badoual C, Fouquet S, et al. (2011) Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Invest Dermatol 131: 1300-1307.
42. Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, et al. (2004) Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 172: 5450-5455.